Cost per responder for teclistamab and elranatamab in relapsed or refractory multiple myeloma in the United States.
Saved in:
| Title: | Cost per responder for teclistamab and elranatamab in relapsed or refractory multiple myeloma in the United States. |
|---|---|
| Authors: | Gordan LN; Florida Cancer Specialists & Research Institute, Gainesville, FL, USA., Bensimon AG; Analysis Group, Inc, Boston, MA, USA., Mu F; Analysis Group, Inc, Boston, MA, USA., Kim N; Johnson & Johnson, Horsham, PA, USA., Wu B; Johnson & Johnson, Horsham, PA, USA., Lin D; Johnson & Johnson, Horsham, PA, USA., Paner A; Johnson & Johnson, Horsham, PA, USA., Fowler J; Johnson & Johnson, Horsham, PA, USA., Marshall A; Johnson & Johnson, LLC, Raritan, NJ, USA., Van Sanden S; Johnson & Johnson NV, Beerse, Belgium., Ammann E; Johnson & Johnson, LLC, Raritan, NJ, USA., Goble J; Johnson & Johnson, Horsham, PA, USA., Zhang X; Johnson & Johnson, Horsham, PA, USA., Le HH; Johnson & Johnson, Horsham, PA, USA., Min EE; Johnson & Johnson, Horsham, PA, USA.; Purdue University College of Pharmacy, West Lafayette, IN, USA., Garrison LP Jr; University of Washington, School of Pharmacy, Seattle, WA, USA. |
| Source: | Journal of medical economics [J Med Econ] 2025 Dec; Vol. 28 (1), pp. 910-920. Date of Electronic Publication: 2025 Jun 14. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Taylor & Francis Country of Publication: England NLM ID: 9892255 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1941-837X (Electronic) Linking ISSN: 13696998 NLM ISO Abbreviation: J Med Econ Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1941-837X |
|---|---|
| DOI: | 10.1080/13696998.2025.2514909 |
